Nanorobots the Future of Neurology: A Perspective on Alzheimer’s Disease

Nanorobots are complex machines measured in nanometers that operate at the molecular level inside patients. In the future these small nanoscale machines could potentially be used as biosensors to screen for disease, to combat pathological cellular or molecular processes or to deliver medication to precise locations. Nanorobots are akin to manipulatable electronic white blood cells that patrol the body. A nanorobot in the form of a micro-rocket has already been shown to bind and transport cancer cells in physiological fluids in vitro (1) and micromotors have been developed to deliver cargo via self-propulsion to the stomach in mice (2). Moreover, in 2016 Fraser Stoddart, Bernard Feringa and Jean-Pierre Sauvage won the Nobel Prize in chemistry for their work in the development of nanomachines in which they utilised chemical energy to create motion (3). Collectively, these breakthroughs are paving the way for the design of more complex nanorobots for medicinal use. The aim of this editorial is to inspire further research in the new field of nanorobotics for the prevention of Alzheimer’s disease (AD) and other neurological disorders.

[1]  Susana Campuzano,et al.  Micromachine-enabled capture and isolation of cancer cells in complex media. , 2011, Angewandte Chemie.

[2]  Shankar Vallabhajosula,et al.  Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study , 2014, BMJ Open.

[3]  J. Palmblad,et al.  ω-3 fatty acids in the prevention of cognitive decline in humans. , 2013, Advances in nutrition.

[4]  B. Vellas,et al.  Cross‐sectional associations of cortical β‐amyloid with erythrocyte membrane long‐chain polyunsaturated fatty acids in older adults with subjective memory complaints , 2017, Journal of neurochemistry.

[5]  Jonathan C Barnes,et al.  Profile of Jean-Pierre Sauvage, Sir J. Fraser Stoddart, and Bernard L. Feringa, 2016 Nobel Laureates in Chemistry , 2017, Proceedings of the National Academy of Sciences.

[6]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Nadjar,et al.  Anti-Inflammatory Effects of Omega-3 Fatty Acids in the Brain: Physiological Mechanisms and Relevance to Pharmacology , 2018, Pharmacological Reviews.

[8]  A. Smith,et al.  Dementia Prevention by Disease-Modification through Nutrition. , 2017, The journal of prevention of Alzheimer's disease.

[9]  M. Pahor,et al.  The Relationship of Omega 3 Polyunsaturated Fatty Acids in Red Blood Cell Membranes with Cognitive Function and Brain Structure: A Review Focussed on Alzheimer’s Disease , 2017, The Journal of Prevention of Alzheimer's Disease.

[10]  C. Annweiler,et al.  Associations of lower vitamin D concentrations with cognitive decline and long-term risk of dementia and Alzheimer's disease in older adults , 2017, Alzheimer's & Dementia.

[11]  D. Holtzman,et al.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Eric D. Vidoni,et al.  Impaired glycemia increases disease progression in mild cognitive impairment , 2014, Neurobiology of Aging.

[13]  J. Delrieu,et al.  Association of cortical β-amyloid with erythrocyte membrane monounsaturated and saturated fatty acids in older adults at risk of dementia , 2017, The journal of nutrition, health & aging.

[14]  Liangfang Zhang,et al.  Artificial Micromotors in the Mouse’s Stomach: A Step toward in Vivo Use of Synthetic Motors , 2014, ACS nano.

[15]  Nicole C. Burns,et al.  Impaired fasting glucose is associated with increased regional cerebral amyloid , 2016, Neurobiology of Aging.